- Home
- ATXS vs BARK Comparison
ATXS vs BARK Comparison
Compare ATXS & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- BARK
- Stock Information
- Founded
- ATXS 2008
- BARK 2011
- Country
- ATXS United States
- BARK United States
- Employees
- ATXS N/A
- BARK N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- BARK Department/Specialty Retail Stores
- Sector
- ATXS Health Care
- BARK Consumer Discretionary
- Exchange
- ATXS Nasdaq
- BARK Nasdaq
- Market Cap
- ATXS 401.2M
- BARK 342.7M
- IPO Year
- ATXS 2015
- BARK N/A
- Fundamental
- Price
- ATXS $5.34
- BARK $1.40
- Analyst Decision
- ATXS Strong Buy
- BARK Buy
- Analyst Count
- ATXS 5
- BARK 2
- Target Price
- ATXS $26.60
- BARK $2.50
- AVG Volume (30 Days)
- ATXS 276.5K
- BARK 874.2K
- Earning Date
- ATXS 03-11-2025
- BARK 02-05-2025
- Dividend Yield
- ATXS N/A
- BARK N/A
- EPS Growth
- ATXS N/A
- BARK N/A
- EPS
- ATXS N/A
- BARK N/A
- Revenue
- ATXS N/A
- BARK $490,256,000.00
- Revenue This Year
- ATXS N/A
- BARK $3.12
- Revenue Next Year
- ATXS N/A
- BARK $7.76
- P/E Ratio
- ATXS N/A
- BARK N/A
- Revenue Growth
- ATXS N/A
- BARK N/A
- 52 Week Low
- ATXS $5.29
- BARK $1.01
- 52 Week High
- ATXS $14.04
- BARK $2.56
- Technical
- Relative Strength Index (RSI)
- ATXS 28.85
- BARK 38.56
- Support Level
- ATXS $5.89
- BARK $1.35
- Resistance Level
- ATXS $6.52
- BARK $1.48
- Average True Range (ATR)
- ATXS 0.40
- BARK 0.08
- MACD
- ATXS -0.06
- BARK 0.02
- Stochastic Oscillator
- ATXS 2.50
- BARK 52.78
Stock Price Comparison Chart: ATXS vs BARK
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.